Effect of hydroxychloroquine on prevention of COVID-19 virus infection among healthcare professionals: a structured summary of a study protocol for a randomised controlled trial.
Identifieur interne : 001515 ( Main/Corpus ); précédent : 001514; suivant : 001516Effect of hydroxychloroquine on prevention of COVID-19 virus infection among healthcare professionals: a structured summary of a study protocol for a randomised controlled trial.
Auteurs : Reihaneh Pirjani ; Tahereh Soori ; Ahmad Reza Dehpour ; Mahdi Sepidarkish ; Ashraf Moini ; Arshia Shizarpour ; Razieh Mohammad JafariSource :
- Trials [ 1745-6215 ] ; 2020.
English descriptors
- KwdEn :
- Antiviral Agents (administration & dosage), Antiviral Agents (adverse effects), Betacoronavirus (drug effects), Betacoronavirus (pathogenicity), COVID-19 (MeSH), Chemoprevention (MeSH), Coronavirus Infections (diagnosis), Coronavirus Infections (prevention & control), Coronavirus Infections (virology), Double-Blind Method (MeSH), Humans (MeSH), Hydroxychloroquine (administration & dosage), Hydroxychloroquine (adverse effects), Infectious Disease Transmission, Patient-to-Professional (prevention & control), Iran (MeSH), Occupational Exposure (adverse effects), Occupational Health (MeSH), Pandemics (prevention & control), Pneumonia, Viral (diagnosis), Pneumonia, Viral (prevention & control), Pneumonia, Viral (virology), Randomized Controlled Trials as Topic (MeSH), Risk Assessment (MeSH), Risk Factors (MeSH), SARS-CoV-2 (MeSH), Time Factors (MeSH), Treatment Outcome (MeSH).
- MESH :
- chemical , administration & dosage : Antiviral Agents, Hydroxychloroquine.
- chemical , adverse effects : Antiviral Agents, Hydroxychloroquine.
- geographic : Iran.
- adverse effects : Occupational Exposure.
- diagnosis : Coronavirus Infections, Pneumonia, Viral.
- drug effects : Betacoronavirus.
- pathogenicity : Betacoronavirus.
- prevention & control : Coronavirus Infections, Infectious Disease Transmission, Patient-to-Professional, Pandemics, Pneumonia, Viral.
- virology : Coronavirus Infections, Pneumonia, Viral.
- COVID-19, Chemoprevention, Double-Blind Method, Humans, Occupational Health, Randomized Controlled Trials as Topic, Risk Assessment, Risk Factors, SARS-CoV-2, Time Factors, Treatment Outcome.
Abstract
OBJECTIVES
Comparison of the effect of hydroxychloroquine with placebo to prevent infection from the COVID -19 virus among healthcare professionals TRIAL DESIGN: Single centre, 2-arm, double-blind randomised (ratio 1:1) placebo-controlled trial PARTICIPANTS: Treatment staff who are in contact with patients and have at least 3 shifts a week in Arash hospital affiliated with Tehran University of Medical Sciences, in Iran and who consent to participate in the study. Exclusion criteria include: History of COVID -19 virus infection, clinical symptoms such as fever, nausea, dyspnea and myalgia in the past two months, history of underlying diseases hypersensitivity to hydroxychloroquine and G6PD enzyme deficiency.
INTERVENTION AND COMPARATOR
Intervention group: Hydroxychloroquine 200 mg tablet of Amin Pharmaceutical.
CONTROL GROUP
placebo which is completely similar in form and taste to 200 mg hydroxychloroquine tablet and is manufactured by the same factory (Amin Pharmacy). The dosage is two tablets daily, once a week for one to three months (based on the duration of the Coronavirus epidemic in Tehran).
MAIN OUTCOMES
Confirmed COVID-19 virus infection using Polymerase chain reaction (PCR) test is the primary outcome. The time period for measuring the primary outcome is any infection within the trial period up to one month after taking the last dose.
RANDOMISATION
The randomized block allocation method was developed using Stata version 15 software by an independent researcher, using a block size of six. Allocation to the two treatment groups will be conducted by this researcher using paper labels (random 10-digit codes) in a 1:1 ratio t The labels will be attached to the drug packages in order of randomization. Drug packages will be arranged in a box according to the randomization list.
BLINDING (MASKING)
Participants and caregivers are blinded to group assignment and the data will be analyzed by an independent statistical expert who is unaware of the treatment allocation.
NUMBERS TO BE RANDOMISED (SAMPLE SIZE)
A total of 282 participants will be randomised with 141 participants the Hydroxychloroquineeach intervention group and 141 participants to the placebo control group TRIAL STATUS: The protocol version number is 99-1-101-47091 and the approval ID is IR.TUMS.VCR.REC.1399.001 and recruitment began April 7, 2020, and is anticipated to be complete by August 7, 2020.
TRIAL REGISTRATION
The name of the trial register is Iranian registry of clinical trial (IRCT), registration number is IRCT20120826010664N6, date of trial registration is April 7, 2020, FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
DOI: 10.1186/s13063-020-04439-3
PubMed: 32493447
PubMed Central: PMC7267750
Links to Exploration step
pubmed:32493447Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of hydroxychloroquine on prevention of COVID-19 virus infection among healthcare professionals: a structured summary of a study protocol for a randomised controlled trial.</title><author><name sortKey="Pirjani, Reihaneh" sort="Pirjani, Reihaneh" uniqKey="Pirjani R" first="Reihaneh" last="Pirjani">Reihaneh Pirjani</name><affiliation><nlm:affiliation>Department of Obstetrics and Gynecology, Arash Women's Hospital, Tehran University of Medical Sciences, Tehran, Iran. pirjani@razi.tums.ac.ir.</nlm:affiliation></affiliation></author><author><name sortKey="Soori, Tahereh" sort="Soori, Tahereh" uniqKey="Soori T" first="Tahereh" last="Soori">Tahereh Soori</name><affiliation><nlm:affiliation>Department of Infectious Diseases, Arash Hospital, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Dehpour, Ahmad Reza" sort="Dehpour, Ahmad Reza" uniqKey="Dehpour A" first="Ahmad Reza" last="Dehpour">Ahmad Reza Dehpour</name><affiliation><nlm:affiliation>Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Experimental Medicine Research Center, TUMS, Tehan, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Sepidarkish, Mahdi" sort="Sepidarkish, Mahdi" uniqKey="Sepidarkish M" first="Mahdi" last="Sepidarkish">Mahdi Sepidarkish</name><affiliation><nlm:affiliation>Department of Biostatistics and Epidemiology, School of Public Health, Babol University of Medical Sciences, Babol, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Moini, Ashraf" sort="Moini, Ashraf" uniqKey="Moini A" first="Ashraf" last="Moini">Ashraf Moini</name><affiliation><nlm:affiliation>Department of Obstetrics and Gynecology, Arash Women's Hospital, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Reproductive Epidemiology Research Center, Royan Institute for Reproductive Biomedicine, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Shizarpour, Arshia" sort="Shizarpour, Arshia" uniqKey="Shizarpour A" first="Arshia" last="Shizarpour">Arshia Shizarpour</name><affiliation><nlm:affiliation>School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Mohammad Jafari, Razieh" sort="Mohammad Jafari, Razieh" uniqKey="Mohammad Jafari R" first="Razieh" last="Mohammad Jafari">Razieh Mohammad Jafari</name><affiliation><nlm:affiliation>Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32493447</idno><idno type="pmid">32493447</idno><idno type="doi">10.1186/s13063-020-04439-3</idno><idno type="pmc">PMC7267750</idno><idno type="wicri:Area/Main/Corpus">001515</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001515</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of hydroxychloroquine on prevention of COVID-19 virus infection among healthcare professionals: a structured summary of a study protocol for a randomised controlled trial.</title><author><name sortKey="Pirjani, Reihaneh" sort="Pirjani, Reihaneh" uniqKey="Pirjani R" first="Reihaneh" last="Pirjani">Reihaneh Pirjani</name><affiliation><nlm:affiliation>Department of Obstetrics and Gynecology, Arash Women's Hospital, Tehran University of Medical Sciences, Tehran, Iran. pirjani@razi.tums.ac.ir.</nlm:affiliation></affiliation></author><author><name sortKey="Soori, Tahereh" sort="Soori, Tahereh" uniqKey="Soori T" first="Tahereh" last="Soori">Tahereh Soori</name><affiliation><nlm:affiliation>Department of Infectious Diseases, Arash Hospital, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Dehpour, Ahmad Reza" sort="Dehpour, Ahmad Reza" uniqKey="Dehpour A" first="Ahmad Reza" last="Dehpour">Ahmad Reza Dehpour</name><affiliation><nlm:affiliation>Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Experimental Medicine Research Center, TUMS, Tehan, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Sepidarkish, Mahdi" sort="Sepidarkish, Mahdi" uniqKey="Sepidarkish M" first="Mahdi" last="Sepidarkish">Mahdi Sepidarkish</name><affiliation><nlm:affiliation>Department of Biostatistics and Epidemiology, School of Public Health, Babol University of Medical Sciences, Babol, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Moini, Ashraf" sort="Moini, Ashraf" uniqKey="Moini A" first="Ashraf" last="Moini">Ashraf Moini</name><affiliation><nlm:affiliation>Department of Obstetrics and Gynecology, Arash Women's Hospital, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Reproductive Epidemiology Research Center, Royan Institute for Reproductive Biomedicine, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Shizarpour, Arshia" sort="Shizarpour, Arshia" uniqKey="Shizarpour A" first="Arshia" last="Shizarpour">Arshia Shizarpour</name><affiliation><nlm:affiliation>School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Mohammad Jafari, Razieh" sort="Mohammad Jafari, Razieh" uniqKey="Mohammad Jafari R" first="Razieh" last="Mohammad Jafari">Razieh Mohammad Jafari</name><affiliation><nlm:affiliation>Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Trials</title><idno type="eISSN">1745-6215</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (administration & dosage)</term><term>Antiviral Agents (adverse effects)</term><term>Betacoronavirus (drug effects)</term><term>Betacoronavirus (pathogenicity)</term><term>COVID-19 (MeSH)</term><term>Chemoprevention (MeSH)</term><term>Coronavirus Infections (diagnosis)</term><term>Coronavirus Infections (prevention & control)</term><term>Coronavirus Infections (virology)</term><term>Double-Blind Method (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (administration & dosage)</term><term>Hydroxychloroquine (adverse effects)</term><term>Infectious Disease Transmission, Patient-to-Professional (prevention & control)</term><term>Iran (MeSH)</term><term>Occupational Exposure (adverse effects)</term><term>Occupational Health (MeSH)</term><term>Pandemics (prevention & control)</term><term>Pneumonia, Viral (diagnosis)</term><term>Pneumonia, Viral (prevention & control)</term><term>Pneumonia, Viral (virology)</term><term>Randomized Controlled Trials as Topic (MeSH)</term><term>Risk Assessment (MeSH)</term><term>Risk Factors (MeSH)</term><term>SARS-CoV-2 (MeSH)</term><term>Time Factors (MeSH)</term><term>Treatment Outcome (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Iran</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Occupational Exposure</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term><term>Infectious Disease Transmission, Patient-to-Professional</term><term>Pandemics</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>COVID-19</term><term>Chemoprevention</term><term>Double-Blind Method</term><term>Humans</term><term>Occupational Health</term><term>Randomized Controlled Trials as Topic</term><term>Risk Assessment</term><term>Risk Factors</term><term>SARS-CoV-2</term><term>Time Factors</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVES</b></p><p>Comparison of the effect of hydroxychloroquine with placebo to prevent infection from the COVID -19 virus among healthcare professionals TRIAL DESIGN: Single centre, 2-arm, double-blind randomised (ratio 1:1) placebo-controlled trial PARTICIPANTS: Treatment staff who are in contact with patients and have at least 3 shifts a week in Arash hospital affiliated with Tehran University of Medical Sciences, in Iran and who consent to participate in the study. Exclusion criteria include: History of COVID -19 virus infection, clinical symptoms such as fever, nausea, dyspnea and myalgia in the past two months, history of underlying diseases hypersensitivity to hydroxychloroquine and G6PD enzyme deficiency.</p></div><div type="abstract" xml:lang="en"><p><b>INTERVENTION AND COMPARATOR</b></p><p>Intervention group: Hydroxychloroquine 200 mg tablet of Amin Pharmaceutical.</p></div><div type="abstract" xml:lang="en"><p><b>CONTROL GROUP</b></p><p>placebo which is completely similar in form and taste to 200 mg hydroxychloroquine tablet and is manufactured by the same factory (Amin Pharmacy). The dosage is two tablets daily, once a week for one to three months (based on the duration of the Coronavirus epidemic in Tehran).</p></div><div type="abstract" xml:lang="en"><p><b>MAIN OUTCOMES</b></p><p>Confirmed COVID-19 virus infection using Polymerase chain reaction (PCR) test is the primary outcome. The time period for measuring the primary outcome is any infection within the trial period up to one month after taking the last dose.</p></div><div type="abstract" xml:lang="en"><p><b>RANDOMISATION</b></p><p>The randomized block allocation method was developed using Stata version 15 software by an independent researcher, using a block size of six. Allocation to the two treatment groups will be conducted by this researcher using paper labels (random 10-digit codes) in a 1:1 ratio t The labels will be attached to the drug packages in order of randomization. Drug packages will be arranged in a box according to the randomization list.</p></div><div type="abstract" xml:lang="en"><p><b>BLINDING (MASKING)</b></p><p>Participants and caregivers are blinded to group assignment and the data will be analyzed by an independent statistical expert who is unaware of the treatment allocation.</p></div><div type="abstract" xml:lang="en"><p><b>NUMBERS TO BE RANDOMISED (SAMPLE SIZE)</b></p><p>A total of 282 participants will be randomised with 141 participants the Hydroxychloroquineeach intervention group and 141 participants to the placebo control group TRIAL STATUS: The protocol version number is 99-1-101-47091 and the approval ID is IR.TUMS.VCR.REC.1399.001 and recruitment began April 7, 2020, and is anticipated to be complete by August 7, 2020.</p></div><div type="abstract" xml:lang="en"><p><b>TRIAL REGISTRATION</b></p><p>The name of the trial register is Iranian registry of clinical trial (IRCT), registration number is IRCT20120826010664N6, date of trial registration is April 7, 2020, FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32493447</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jun</Month><Day>03</Day></PubDate></JournalIssue><Title>Trials</Title><ISOAbbreviation>Trials</ISOAbbreviation></Journal><ArticleTitle>Effect of hydroxychloroquine on prevention of COVID-19 virus infection among healthcare professionals: a structured summary of a study protocol for a randomised controlled trial.</ArticleTitle><Pagination><MedlinePgn>467</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-020-04439-3</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Comparison of the effect of hydroxychloroquine with placebo to prevent infection from the COVID -19 virus among healthcare professionals TRIAL DESIGN: Single centre, 2-arm, double-blind randomised (ratio 1:1) placebo-controlled trial PARTICIPANTS: Treatment staff who are in contact with patients and have at least 3 shifts a week in Arash hospital affiliated with Tehran University of Medical Sciences, in Iran and who consent to participate in the study. Exclusion criteria include: History of COVID -19 virus infection, clinical symptoms such as fever, nausea, dyspnea and myalgia in the past two months, history of underlying diseases hypersensitivity to hydroxychloroquine and G6PD enzyme deficiency.</AbstractText><AbstractText Label="INTERVENTION AND COMPARATOR" NlmCategory="UNASSIGNED">Intervention group: Hydroxychloroquine 200 mg tablet of Amin Pharmaceutical.</AbstractText><AbstractText Label="CONTROL GROUP" NlmCategory="METHODS">placebo which is completely similar in form and taste to 200 mg hydroxychloroquine tablet and is manufactured by the same factory (Amin Pharmacy). The dosage is two tablets daily, once a week for one to three months (based on the duration of the Coronavirus epidemic in Tehran).</AbstractText><AbstractText Label="MAIN OUTCOMES" NlmCategory="RESULTS">Confirmed COVID-19 virus infection using Polymerase chain reaction (PCR) test is the primary outcome. The time period for measuring the primary outcome is any infection within the trial period up to one month after taking the last dose.</AbstractText><AbstractText Label="RANDOMISATION" NlmCategory="UNASSIGNED">The randomized block allocation method was developed using Stata version 15 software by an independent researcher, using a block size of six. Allocation to the two treatment groups will be conducted by this researcher using paper labels (random 10-digit codes) in a 1:1 ratio t The labels will be attached to the drug packages in order of randomization. Drug packages will be arranged in a box according to the randomization list.</AbstractText><AbstractText Label="BLINDING (MASKING)" NlmCategory="UNASSIGNED">Participants and caregivers are blinded to group assignment and the data will be analyzed by an independent statistical expert who is unaware of the treatment allocation.</AbstractText><AbstractText Label="NUMBERS TO BE RANDOMISED (SAMPLE SIZE)" NlmCategory="UNASSIGNED">A total of 282 participants will be randomised with 141 participants the Hydroxychloroquineeach intervention group and 141 participants to the placebo control group TRIAL STATUS: The protocol version number is 99-1-101-47091 and the approval ID is IR.TUMS.VCR.REC.1399.001 and recruitment began April 7, 2020, and is anticipated to be complete by August 7, 2020.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">The name of the trial register is Iranian registry of clinical trial (IRCT), registration number is IRCT20120826010664N6, date of trial registration is April 7, 2020, FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pirjani</LastName><ForeName>Reihaneh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Arash Women's Hospital, Tehran University of Medical Sciences, Tehran, Iran. pirjani@razi.tums.ac.ir.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soori</LastName><ForeName>Tahereh</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Arash Hospital, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dehpour</LastName><ForeName>Ahmad Reza</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Experimental Medicine Research Center, TUMS, Tehan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sepidarkish</LastName><ForeName>Mahdi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Epidemiology, School of Public Health, Babol University of Medical Sciences, Babol, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moini</LastName><ForeName>Ashraf</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Arash Women's Hospital, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Reproductive Epidemiology Research Center, Royan Institute for Reproductive Biomedicine, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shizarpour</LastName><ForeName>Arshia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohammad Jafari</LastName><ForeName>Razieh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trials</MedlineTA><NlmUniqueID>101263253</NlmUniqueID><ISSNLinking>1745-6215</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018890" MajorTopicYN="N">Chemoprevention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017758" MajorTopicYN="N">Infectious Disease Transmission, Patient-to-Professional</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007492" MajorTopicYN="N" Type="Geographic">Iran</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016273" MajorTopicYN="N">Occupational Exposure</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016272" MajorTopicYN="Y">Occupational Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Randomised controlled trial</Keyword><Keyword MajorTopicYN="N">healthcare professionals</Keyword><Keyword MajorTopicYN="N">hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">prevention</Keyword><Keyword MajorTopicYN="N">protocol</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>05</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32493447</ArticleId><ArticleId IdType="doi">10.1186/s13063-020-04439-3</ArticleId><ArticleId IdType="pii">10.1186/s13063-020-04439-3</ArticleId><ArticleId IdType="pmc">PMC7267750</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001515 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001515 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32493447
|texte= Effect of hydroxychloroquine on prevention of COVID-19 virus infection among healthcare professionals: a structured summary of a study protocol for a randomised controlled trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32493447" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |